Traveling for Care?
Whether you're crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.
The Johns Hopkins Family Professor in Oncology Research
Professor of Medicine, Cell Biology, Oncology and Pathology
Vice Dean for Research, School of Medicine
Room 1032, Ross Building
COS profile : http://myprofile.cos.com/cvdang
Anemias, Bone Marrow Failure, Myeloproliferative Disorders
My laboratory is studying the mechanisms underlying the neoplastic activities of the MYC oncogene. MYC encodes a transcription factor, c-Myc, that heterodimerizes with Max to bind specific DNA sequences. We have contributed extensively to the identification of functional domains of the c-Myc protein. We, and others, have found that Myc/Max binds to E-box (CANNTG) sequences to activate transcription and other elements to suppress transcription. We have recently identified thousands putative c-Myc target genes using representational difference analysis and DNA microarray analysis. These genes are part of a growing list of putative c-Myc target genes that are estimated to involve about 10% of genes. We have begun to catalog these genes (www.myc-cancer-gene.org) and are using this database and exploiting phylogenetic footprinting (bioinformatics) to predict in vivo c-Myc binding sequences. The binding regions are validated by a technique we invented, Scanning Chromatin Immunoprecipitation (SChIP). We are currently defining the roles of five selected genes in Myc-mediated phenotypes. Our studies have led to the discovery that c-Myc overexpression activates genes encoding proteins involved in glycolysis and contributes to the Warburg effect or aerobic glycolysis, which is characteristic of essentially all solid tumors. We recently discovered a key role c-Myc in the regulation of mitochondrial homeostasis. In addition, we discovered that c-Myc overexpression contributes to genomic instability by uncoupling S and M phases of the cell cycle; this effect renders c-Myc overexpressing cycle sensitive to anti-mitotics. Our work and those of others have led to the concept that MYC is a central regulator of cell proliferation and cellular metabolism.
1972-1975 University of Michigan, Ann Arbor, MI; B.S. chemistry (highest honors)
1975-1978 Georgetown University, Washington D.C.; Ph.D. chemistry (distinction)
1978-1982 Johns Hopkins University School of Medicine, Baltimore, MD; M.D. (Alpha Omega Alpha)
1982-1983 Internship; Department of Medicine; Johns Hopkins Hospital, Baltimore, MD
1983-1985 Residency; Department of Medicine; Johns Hopkins Hospital, Baltimore, MD
1985-1987 Fellowship; Hematology-Oncology; Cancer Research Institute, UCSF
1987-1991 Assistant Professor of Medicine; Johns Hopkins University, School of Medicine
1990-1995 Assistant Professor of Cell Biology & Anatomy, Assistant Professor of Oncology, Johns Hopkins University
1991-1997 Associate Professor of Medicine, Johns Hopkins University
1993-2003 Director, Division of Hematology, Johns Hopkins University
1994-2000 Deputy Director of Research, Department of Medicine, Johns Hopkins University
1997-present Professor of Medicine, Oncology, Pathology, Johns Hopkins University
2000-present Professor of Cell Biology, Johns Hopkins University